[IPO Spotlight] ADM Korea Listed on KOSDAQ... "Leap to a Global CRO Company"

Providing Total Clinical Services from Trial Design to Approval Agency
Stable Contract Acquisition with 360 Clinical Project References over 17 Years
Clear Growth in Global CRO Market, Aiming for Mutual Growth

[Asia Economy Reporter Jang Hyowon] ADM Korea (CEO Kang Junmo), a contract research organization (CRO), held a press conference on the 14th in Yeouido, Seoul, ahead of its listing on the KOSDAQ market to reveal the company's growth potential and vision.

Kang Jun-mo, CEO of ADM Korea, is explaining about the company at a press conference held in Yeouido on the 14th. Photo by ADM Korea

Kang Junmo, CEO of ADM Korea, stated at the press conference, “ADM Korea is a specialized CRO providing total services from Phase 1 to Phase 3 clinical trials, approval, and post-marketing clinical trials, conducting an average of 15 clinical trials annually with related technology and know-how.” He added, “Including our current branches in Thailand and Vietnam, we plan to expand into 10 Asian countries and the United States. Through this active overseas expansion, we aim to establish ourselves as a leading CRO representing Asia after listing.”

Founded in 2003, ADM Korea is a CRO company providing services across all areas of clinical trials to pharmaceutical companies and bio-ventures. It also operates a post-marketing surveillance agency business that collects patient data ranging from 600 to 3,000 cases over a certain period for new drugs and reports patients' new drug usage experiences to the Ministry of Food and Drug Safety.

ADM Korea's main clients are top-tier domestic pharmaceutical companies, maintaining continuous relationships through successful project references. Notably, about 40% of the approximately 140 clients have contracted more than twice, indicating high service satisfaction.

Last year's sales amounted to 13.12 billion KRW, with operating profit and net profit of 3.53 billion KRW and 3.56 billion KRW respectively, representing increases of 29% in sales, 315% in operating profit, and 445% in net profit compared to the previous year.

ADM Korea's total number of public offering shares is 4.5 million (including employee stock ownership association shares), with a desired public offering price of 2,900 to 3,300 KRW per share. Through this offering, approximately 13.05 billion KRW (based on the lower end of the desired price band) will be raised. Institutional investor demand forecasting will be conducted on the 17th and 18th of this month to finalize the public offering price, followed by general subscription on the 25th and 26th, with listing scheduled for June. The lead underwriter is Hana Financial Investment.

This content was produced with the assistance of AI translation services.